

# David T Miyamoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8948973/publications.pdf>

Version: 2024-02-01

40  
papers

6,423  
citations

249298

26  
h-index

325983

40  
g-index

40  
all docs

40  
docs citations

40  
times ranked

10625  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis. <i>Cell</i> , 2014, 158, 1110-1122.	13.5	1,960
2	Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting of Rare Circulating Tumor Cells. <i>Science Translational Medicine</i> , 2013, 5, 179ra47.	5.8	910
3	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015, 349, 1351-1356.	6.0	614
4	Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer. <i>Science Translational Medicine</i> , 2010, 2, 25ra23.	5.8	474
5	Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells. <i>Cell Reports</i> , 2014, 8, 1905-1918.	2.9	449
6	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer. <i>Cancer Discovery</i> , 2012, 2, 995-1003.	7.7	257
7	The kinesin Eg5 drives poleward microtubule flux in <i>Xenopus laevis</i> egg extract spindles. <i>Journal of Cell Biology</i> , 2004, 167, 813-818.	2.3	168
8	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1123-1128.	3.3	133
9	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	3.3	131
10	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 59-68.	0.9	112
11	Circulating tumour cells—monitoring treatment response in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 401-412.	12.5	110
12	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 288-303.	7.7	107
13	Deformability of Tumor Cells versus Blood Cells. <i>Scientific Reports</i> , 2015, 5, 18542.	1.6	104
14	Expression of $\beta$ -globin by cancer cells promotes cell survival during blood-borne dissemination. <i>Nature Communications</i> , 2017, 8, 14344.	5.8	96
15	Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. <i>Cell Reports</i> , 2016, 17, 2632-2647.	2.9	93
16	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 1286-1299.	7.7	85
17	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , The, 2018, 19, e683-e695.	5.1	74
18	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	3.2	71

#	ARTICLE	IF	CITATIONS
19	Concurrent Chemoradiation for Vaginal Cancer. PLoS ONE, 2013, 8, e65048.	1.1	58
20	Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nature Communications, 2017, 8, 1733.	5.8	53
21	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
22	Outcomes with image-based interstitial brachytherapy for vaginal cancer. Radiotherapy and Oncology, 2016, 120, 486-492.	0.3	42
23	Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 269-274.	2.0	40
24	Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Years or Older. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1171-1177.	0.4	34
25	COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5223-5232.	3.3	34
26	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology, 2020, 3, 420-423.	2.6	29
27	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2017, 23, 363-369.	3.2	23
28	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. Advanced Drug Delivery Reviews, 2018, 125, 122-131.	6.6	21
29	Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Frontiers in Oncology, 2021, 11, 663852.	1.3	19
30	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
31	Molecular Predictors of Local Tumor Control in Early-Stage Breast Cancer. Seminars in Radiation Oncology, 2011, 21, 35-42.	1.0	15
32	The promise of circulating tumor cells for precision cancer therapy. Biomarkers in Medicine, 2016, 10, 1269-1285.	0.6	11
33	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 490-501.	0.8	11
34	Dynamics of the mitotic spindle--potential therapeutic targets. Progress in Cell Cycle Research, 2003, 5, 349-60.	0.9	7
35	Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt". Expert Review of Molecular Diagnostics, 2020, 20, 245-254.	1.5	4
36	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Practical Radiation Oncology, 2018, 8, 206-212.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69â€“70. European Urology, 2019, 76, 71-72.	0.9	2
38	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 201-208.	0.8	2
39	Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition. Cancer Research, 2022, 82, 1084-1097.	0.4	2
40	PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer. European Urology, 2020, 78, 845-846.	0.9	1